Floatz Rating
C39/100
Confidence
Indicative
Sponsor
BeOne Medicines
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07226349CT.gov A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06253195CT.gov BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT06257264CT.gov A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | — | Active Not Recruiting | — | — | — |
NCT06120283CT.gov BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bgb-43395 (this asset) | BeOne Medicines | P1 | C · 39 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P4 | BB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Fluorouracilum | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | InSilico Medicine Hong Kong Limited | P4 | BB |
| Trametinib | Cancer Research UK | P2/3 | BB |
+42 more in the Cancer cohort
Other indications for Bgb-43395
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P3 | B · 61 |
| Breast Tumor Luminal A Or B | — | P1 | CC · 41 |
| Gastroesophageal Cancer | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bgb-43395 in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/bgb-43395-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →